EXtension of Tablo TrEatmeNt Duration Registry

N/ACompletedNCT04912050

Outset Medical33 enrolled

Overview

Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.

Study Type

OBSERVATIONAL

Enrollment

Conditions

End Stage Renal Disease (ESRD)End Stage Renal Disease on Dialysis Acute Kidney Injury

Interventions

Tablo Hemodialysis SystemDEVICE

Renal Replacement Therapy between 12\< to ≤ 24 hours.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Participant weighs ≥ 34kg. * Participant is hospitalized and has dialysis dependent End-Stage Kidney Disease or Acute Kidney Injury and is prescribed renal replacement therapy \> 12 hours. Exclusion Criteria: * Any documented condition that the Physician feels would prevent the participant from successful inclusion in the study.

Locations (1)

St. Mark's Hospital

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Treatment Success

Percentage of treatments achieving prescribed dialysis treatment time ≤ 10%

Time frame: Up to 24 hours

Secondary Outcomes

Tablo Cartridge Life

Measure the average number of cartridge changes required to complete a Tablo XT Treatment

Time frame: up to 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.